Financial Contrast: Quoin Pharmaceuticals (NASDAQ:QNRX) and CERo Therapeutics (NASDAQ:CERO)

Quoin Pharmaceuticals (NASDAQ:QNRX) and CERo Therapeutics (NASDAQ:CERO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Risk & Volatility

Quoin Pharmaceuticals has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, CERo Therapeutics has a beta of 0.09, suggesting that its share price is 91% less volatile than the S&P 500.

Valuation and Earnings

This table compares Quoin Pharmaceuticals and CERo Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quoin Pharmaceuticals	N/A	N/A	-$15.81 million	($29.56)	-0.11
CERo Therapeutics	N/A	N/A	-$8.30 million	($71.01)	0.00

Quoin Pharmaceuticals is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

8.6% of Quoin Pharmaceuticals shares are held by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are held by institutional investors. 13.5% of Quoin Pharmaceuticals shares are held by insiders. Comparatively, 0.4% of CERo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Quoin Pharmaceuticals and CERo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%
CERo Therapeutics	N/A	N/A	-209.40%

Analyst Ratings

This is a summary of current recommendations and price targets for Quoin Pharmaceuticals and CERo Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quoin Pharmaceuticals	1	0	1	0	2.00
CERo Therapeutics	1	2	0	0	1.67

CERo Therapeutics has a consensus target price of $30.00, indicating a potential upside of 322,480.65%. Given CERo Therapeutics’ higher possible upside, analysts plainly believe CERo Therapeutics is more favorable than Quoin Pharmaceuticals.

Summary

CERo Therapeutics beats Quoin Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.